Skip to main content
SpringerLink
Log in
Book cover

Pediatric Metabolic Syndrome pp 137–157Cite as

Metabolic Syndrome and Related Liver Diseases

  • Chapter
  • First Online:

  • 920 Accesses

Abstract

The metabolic syndrome is often accompanied by liver disease, specifically nonalcoholic fatty liver disease (NAFLD). NAFLD is a clinicopathological entity characterized by accumulation of fat in the liver in the setting of minimal to no alcohol intake. It represents a spectrum of liver disease ranging from steatosis to advanced fibrosis or cirrhosis and can lead to hepatocellular carcinoma. The causes of NAFLD are multifactorial and include genetic predisposition and environmental factors including overnutrition. NAFLD is not a defining characteristic of the metabolic syndrome, but these conditions frequently coexist, especially in the setting of obesity. The prevalence of NAFLD in pediatrics has not been clearly determined, but this is considered the most common pediatric liver disease. An important challenge is that NAFLD is typically asymptomatic and is usually not diagnosed unless the clinician specifically evaluates the patient for it. The diagnosis of NAFLD is established through a liver biopsy. There are pathogenetic links between NAFLD and the metabolic syndrome, but the precise pathogeneses of these conditions remain to be fully elucidated. The effects of NAFLD on the natural history of the metabolic syndrome, and vice versa, are not known. However, it is possible that these conditions may exacerbate one another. Further research is needed to answer important questions regarding pediatric NAFLD and its relationship to the metabolic syndrome. What is clear is that given the high prevalence of overweight and obesity, clinicians need to be well informed about the risk of liver disease in the patient with metabolic syndrome.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Feldstein AE, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58(11):1538–44.

    PubMed  CAS  Google Scholar 

  2. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67(5):811–6.

    PubMed  CAS  Google Scholar 

  3. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

    PubMed  CAS  Google Scholar 

  4. Moran JR, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78:374–7.

    PubMed  Google Scholar 

  5. Alisi A, et al. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr. 2009;155(4):469–74.

    PubMed  Google Scholar 

  6. Loomba R, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50(4):1282–93.

    PubMed  CAS  Google Scholar 

  7. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    PubMed  Google Scholar 

  8. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136(6):727–33.

    PubMed  CAS  Google Scholar 

  9. Park HS, et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr. 2005;82(5):1046–51.

    PubMed  CAS  Google Scholar 

  10. Schwimmer JB, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388–93.

    PubMed  Google Scholar 

  11. Franzese A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42(7):1428–32.

    PubMed  CAS  Google Scholar 

  12. Chan DF, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004;28(10):1257–63.

    PubMed  CAS  Google Scholar 

  13. Tazawa Y, et al. Serum alanine aminotransferase activity in obese children. Acta Paediatr. 1997;86(3):238–41.

    PubMed  CAS  Google Scholar 

  14. Manton ND, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust. 2000;173(9):476–9.

    PubMed  CAS  Google Scholar 

  15. Schwimmer JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143(4):500–5.

    PubMed  Google Scholar 

  16. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30(1):48–53.

    PubMed  CAS  Google Scholar 

  17. Nguyen TT, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr. 2001;138(4):474–80.

    PubMed  CAS  Google Scholar 

  18. Fishbein MH, et al. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr. 2003;36(1):54–61.

    PubMed  CAS  Google Scholar 

  19. Taylor KJ, et al. Ultrasonography of alcoholic liver disease with histological correlation. Radiology. 1981;141(1):157–61.

    PubMed  CAS  Google Scholar 

  20. Needleman L, et al. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol. 1986;146(5):1011–5.

    PubMed  CAS  Google Scholar 

  21. Mathiesen UL, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002;34(7):516–22.

    PubMed  CAS  Google Scholar 

  22. Celle G, et al. Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci. 1988;33(4):467–71.

    PubMed  CAS  Google Scholar 

  23. Bydder GM, et al. Computed tomography attenuation values in fatty liver. J Comput Tomogr. 1981;5(1):33–5.

    PubMed  CAS  Google Scholar 

  24. Jacobs JE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998;171(3):659–64.

    PubMed  CAS  Google Scholar 

  25. Rinella ME, et al. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: implications for living liver donation. Liver Transpl. 2003;9(8):851–6.

    PubMed  Google Scholar 

  26. Fishbein MH, et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997;15(3):287–93.

    PubMed  CAS  Google Scholar 

  27. Nobili V, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48(2):442–8.

    PubMed  CAS  Google Scholar 

  28. Yoneda M, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371–8.

    PubMed  CAS  Google Scholar 

  29. Huwart L, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.

    PubMed  Google Scholar 

  30. Baldridge AD, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995;127(5):700–4.

    PubMed  CAS  Google Scholar 

  31. Schwimmer JB, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42(3):641–9.

    PubMed  Google Scholar 

  32. Molleston JP, et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002;97(9):2460–2.

    PubMed  Google Scholar 

  33. Jonas MM, et al. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome. Liver Transpl. 2005;11(1):108–10.

    PubMed  Google Scholar 

  34. Adams LA, et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39(4):909–14.

    PubMed  Google Scholar 

  35. Cuadrado A, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg. 2005;15(3):442–6.

    PubMed  Google Scholar 

  36. Schwimmer JB, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118(3):277–83.

    PubMed  CAS  Google Scholar 

  37. Demircioglu F, et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008;47(1):68–75.

    PubMed  Google Scholar 

  38. Pacifico L, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res. 2008;63(4):423–7.

    PubMed  CAS  Google Scholar 

  39. Norman D, et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008;31(1):121–6.

    PubMed  Google Scholar 

  40. Gardner CJ, et al. Hypothyroidism in a patient with non-alcoholic fatty liver disease. BMJ. 2011;342:c7199.

    PubMed  CAS  Google Scholar 

  41. Lee TH, et al. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47(3):880–7.

    PubMed  Google Scholar 

  42. Schindhelm RK, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22(6):437–43.

    PubMed  CAS  Google Scholar 

  43. Di Bonito P, et al. Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. Metabolism. 2009;58(3):368–72.

    PubMed  Google Scholar 

  44. Wei C, et al. Abnormal liver function in children with metabolic syndrome from a UK-based obesity clinic. Arch Dis Child. 2011;96:1003–7. doi:10.1136/adc.2010.190975.

    PubMed  Google Scholar 

  45. van Vliet M, et al. The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin. Eur J Pediatr. 2009;168(5):585–91.

    PubMed  Google Scholar 

  46. Patel DA, et al. Serum alanine aminotransferase and its association with metabolic syndrome in children: the bogalusa heart study. Metab Syndr Relat Disord. 2011;9(3):211–6.

    PubMed  CAS  Google Scholar 

  47. Marchesini G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

    PubMed  Google Scholar 

  48. Fan JG, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005;20(12):1825–32.

    PubMed  Google Scholar 

  49. Kim HC, et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol. 2005;11(34):5314–21.

    PubMed  Google Scholar 

  50. Hamaguchi M, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8.

    PubMed  CAS  Google Scholar 

  51. Love-Osborne KA, et al. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health. 2008;42(6):543–8.

    PubMed  Google Scholar 

  52. Tominaga K, et al. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med. 2009;14(2):142–9.

    PubMed  CAS  Google Scholar 

  53. Kelishadi R, et al. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol Metab Syndr. 2009;1:29.

    PubMed  Google Scholar 

  54. Fu JF, et al. Non-alcoholic fatty liver disease: an early mediator predicting metabolic syndrome in obese children? World J Gastroenterol. 2011;17(6):735–42.

    PubMed  Google Scholar 

  55. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.

    Google Scholar 

  56. Manco M, et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32(2):381–7.

    CAS  Google Scholar 

  57. Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. World J Gastroenterol. 2010;16(42):5280–5.

    PubMed  Google Scholar 

  58. Nobili V, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44(2):458–65.

    PubMed  Google Scholar 

  59. Patton HM, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol. 2010;105(9):2093–102.

    PubMed  Google Scholar 

  60. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104–12.

    PubMed  Google Scholar 

  61. Alisi A, et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med. 2011. doi:10.3109/07853890.2010.547869.

  62. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.

    PubMed  CAS  Google Scholar 

  63. Musso G, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37(4):909–16.

    PubMed  CAS  Google Scholar 

  64. Cortez-Pinto H, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282(17):1659–64.

    PubMed  CAS  Google Scholar 

  65. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13(4):545–63.

    PubMed  Google Scholar 

  66. Boden G, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005;54(12):3458–65.

    PubMed  CAS  Google Scholar 

  67. Park SH, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19(6):694–8.

    PubMed  CAS  Google Scholar 

  68. Kral JG, et al. Hepatic lipid metabolism in severe human obesity. Metabolism. 1977;26(9):1025–31.

    PubMed  CAS  Google Scholar 

  69. Sanyal AJ, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120(5):1183–92.

    PubMed  CAS  Google Scholar 

  70. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr. 2009;21(4):529–35.

    PubMed  Google Scholar 

  71. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.

    PubMed  CAS  Google Scholar 

  72. Fleischmann M, Iynedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J. 2000;349(Pt 1):13–7.

    PubMed  CAS  Google Scholar 

  73. Shimomura I, et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. 1999;96(24):13656–61.

    PubMed  CAS  Google Scholar 

  74. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19(10):371–9.

    PubMed  CAS  Google Scholar 

  75. Malaguarnera M, et al. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87(7):679–95.

    PubMed  CAS  Google Scholar 

  76. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774–88.

    PubMed  Google Scholar 

  77. Louthan MV, et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr. 2005;147(6):835–8.

    PubMed  CAS  Google Scholar 

  78. Nobili V, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol. 2006;155(5):735–43.

    PubMed  CAS  Google Scholar 

  79. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51(1):212–23.

    PubMed  CAS  Google Scholar 

  80. O’Sullivan TA, et al. Dietary glycaemic carbohydrate in relation to the metabolic syndrome in adolescents: comparison of different metabolic syndrome definitions. Diabet Med. 2010;27(7):770–8.

    PubMed  Google Scholar 

  81. Aeberli I, et al. Diet determines features of the metabolic syndrome in 6- to 14-year-old children. Int J Vitam Nutr Res. 2009;79(1):14–23.

    PubMed  CAS  Google Scholar 

  82. Chu NF, Chang JB, Shieh SM. Plasma leptin, fatty acids, and tumor necrosis factor-receptor and insulin resistance in children. Obes Res. 2003;11(4):532–40.

    PubMed  CAS  Google Scholar 

  83. Turi S, et al. Oxidative stress in juvenile essential hypertension. J Hypertens. 2003;21(1):145–52.

    PubMed  CAS  Google Scholar 

  84. Sinaiko AR, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation. 2005;111(15):1985–91.

    PubMed  CAS  Google Scholar 

  85. Kelly AS, et al. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr. 2006;1(4):248–52.

    PubMed  Google Scholar 

  86. Korner A, et al. New predictors of the metabolic syndrome in children – role of adipocytokines. Pediatr Res. 2007;61(6):640–5.

    PubMed  Google Scholar 

  87. Calcaterra V, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta Biomed. 2009;80(2):117–23.

    PubMed  Google Scholar 

  88. Hales CN, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303(6809):1019–22.

    PubMed  CAS  Google Scholar 

  89. Geremia C, Cianfarani S. Insulin sensitivity in children born small for gestational age (SGA). Rev Diabet Stud. 2004;1(2):58–65.

    PubMed  Google Scholar 

  90. Levy-Marchal C, Czernichow P. Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies? Horm Res. 2006;65 Suppl 3:123–30.

    PubMed  CAS  Google Scholar 

  91. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5–20.

    PubMed  CAS  Google Scholar 

  92. Ross MG, Beall MH. Adult sequelae of intrauterine growth restriction. Semin Perinatol. 2008;32(3):213–8.

    PubMed  Google Scholar 

  93. Godfrey KM, et al. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007;61(5 Pt 2):5R–10.

    PubMed  Google Scholar 

  94. Nobili V, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care. 2007;30(10):2638–40.

    PubMed  Google Scholar 

  95. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108(1):9–13.

    PubMed  CAS  Google Scholar 

  96. Willner IR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96(10):2957–61.

    PubMed  CAS  Google Scholar 

  97. Browning JD, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.

    PubMed  Google Scholar 

  98. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc. 2010;69(2):211–20.

    PubMed  CAS  Google Scholar 

  99. Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5.

    PubMed  CAS  Google Scholar 

  100. Hoekstra M, et al. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol. 2010;52(2):244–51.

    PubMed  CAS  Google Scholar 

  101. Sookoian SC, Gonzalez C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res. 2005;13(12):2122–31.

    PubMed  Google Scholar 

  102. Sookoian S, et al. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome. Am J Hypertens. 2005;18(10):1271–5.

    PubMed  CAS  Google Scholar 

  103. Vasseur F, Meyre D, Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med. 2006;8(27):1–12.

    PubMed  Google Scholar 

  104. Ferguson JF, et al. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr. 2010;91(3):794–801.

    PubMed  CAS  Google Scholar 

  105. Zak A, et al. The influence of polymorphism of -493 G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. J Nutr Biochem. 2008;19(9):634–41.

    PubMed  CAS  Google Scholar 

  106. Robitaille J, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49(9):482–9.

    PubMed  CAS  Google Scholar 

  107. Phillips CM, et al. Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. J Nutr. 2010;140(2):238–44.

    PubMed  CAS  Google Scholar 

  108. Stancakova A, et al. Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res. 2006;55(5):483–90.

    PubMed  CAS  Google Scholar 

  109. Zhou YJ, et al. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol. 2010;25(4):772–7.

    PubMed  CAS  Google Scholar 

  110. Vimaleswaran KS, et al. Absence of association of metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians. Metab Syndr Relat Disord. 2007;5(2):153–62.

    PubMed  CAS  Google Scholar 

  111. Johansson LE, et al. Genetic variance in the adiponutrin gene family and childhood obesity. PLoS One. 2009;4(4):e5327.

    PubMed  Google Scholar 

  112. Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009;49(4):442–9.

    PubMed  Google Scholar 

  113. Hossain N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9, 1229 e1–2.

    PubMed  CAS  Google Scholar 

  114. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–62.

    PubMed  CAS  Google Scholar 

  115. D’Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100(7):1509–15.

    PubMed  Google Scholar 

  116. Svegliati-Baroni G, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29(6):1743–51.

    PubMed  CAS  Google Scholar 

  117. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):521–33, viii.

    PubMed  Google Scholar 

  118. Hesham AKH. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr. 2009;5(4):245–54.

    Google Scholar 

  119. Nielsen S, et al. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113(11):1582–8.

    PubMed  CAS  Google Scholar 

  120. Donnelly KL, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–51.

    PubMed  CAS  Google Scholar 

  121. Kelley DE, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003;285(4):E906–16.

    PubMed  CAS  Google Scholar 

  122. Uusitupa M, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52(10):2532–8.

    PubMed  CAS  Google Scholar 

  123. Schindhelm RK, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191(2):391–6.

    PubMed  CAS  Google Scholar 

  124. Schindhelm RK, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35(6):369–74.

    PubMed  CAS  Google Scholar 

  125. Ekstedt M, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.

    PubMed  CAS  Google Scholar 

  126. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets. 2008;8(4):301–7.

    PubMed  CAS  Google Scholar 

  127. Amaral JF, Thompson WR. Gallbladder disease in the morbidly obese. Am J Surg. 1985;149(4):551–7.

    PubMed  CAS  Google Scholar 

  128. Baker S, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40(5):533–43.

    PubMed  Google Scholar 

  129. Petersen KF, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603–8.

    PubMed  CAS  Google Scholar 

  130. Ebbeling CB, et al. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297(19):2092–102.

    PubMed  CAS  Google Scholar 

  131. Benjaminov O, et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc. 2007;21(8):1423–7.

    PubMed  CAS  Google Scholar 

  132. Lavine JE, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–68.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatrics/Gastroenterology, University of Miami, 1580 NW 10th Avenue, Room 523, 33136, Miami, FL, USA

    Aymin Delgado-Borrego M.D., MPH

Authors
  1. Aymin Delgado-Borrego M.D., MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aymin Delgado-Borrego M.D., MPH .

Editor information

Editors and Affiliations

  1. , Pediatrics, Miller School of Medicine, D820, Miami, 33101-6820, Florida, USA

    Steven E. Lipshultz

  2. , Pediatrics, Miller School of Medicine, 1580 NW 10th Avenue, Miami, 33130, USA

    Sarah E. Messiah

  3. , Pediatrics, Miller School of Medicine, 1580 NW 10th Avenue #123, Miami, 33101, USA

    Tracie L. Miller

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag London

About this chapter

Cite this chapter

Delgado-Borrego, A. (2012). Metabolic Syndrome and Related Liver Diseases. In: Lipshultz, S., Messiah, S., Miller, T. (eds) Pediatric Metabolic Syndrome. Springer, London. https://doi.org/10.1007/978-1-4471-2366-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2366-8_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2365-1

  • Online ISBN: 978-1-4471-2366-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation